Reblozyl (luspatercept)
An approved treatment for Beta-Thalassemia.
The same compound appears under different names depending on the context. Here is how to identify Luspatercept wherever you encounter it, plus the key facts at a glance.
- Generic name
- Luspatercept
- Brand name
- Reblozyl
- Development code
- ACE-536
- Drug class
- Erythroid maturation agent
- Manufacturer
- Bristol Myers Squibb (licensed from Merck/Acceleron Pharma)
- How it's taken
- Given as a subcutaneous injection once every 3 weeks.
The first drug approved specifically for anemia in beta-thalassemia patients who require regular blood transfusions. Reblozyl helps the body mature its own red blood cells more effectively, reducing the need for transfusions.
We'll email you when Reblozyl's FDA label changes, when the FDA acts on it, and when new trials for Thalassemia open. Unsubscribe anytime.
Where Luspatercept fits
First therapy specifically approved to reduce transfusion burden in beta-thalassemia. Used for adult patients who require regular red blood cell transfusions, potentially reducing transfusion frequency.
How Luspatercept works
In beta-thalassemia, the body produces defective hemoglobin, leading to ineffective red blood cell production. Immature red blood cells die before they mature.
Luspatercept acts as a trap for certain growth factors (TGF-beta superfamily ligands) that block the final stages of red blood cell development. By removing these blockers, it allows more red blood cells to fully mature and enter the bloodstream.
Mechanism: Erythroid maturation agent that promotes late-stage red blood cell development by trapping TGF-beta superfamily ligands
Side effects and safety
Common side effects include headache, bone pain, joint pain, fatigue, cough, abdominal pain, diarrhea, and dizziness. Thromboembolic events (blood clots) have been reported. Blood pressure should be monitored. In beta-thalassemia, extramedullary hematopoietic masses can form and occasionally press on the spinal cord. May harm a developing baby; use effective birth control during treatment and for 3 months after.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Luspatercept
Given as a subcutaneous injection once every 3 weeks. Starting dose is 1 mg/kg, which can be titrated up to 1.25 mg/kg based on response. It is mixed and given by a healthcare professional, and hemoglobin is checked before each dose.
Availability and cost
Only available as the brand-name product.
First-in-class erythroid maturation agent (modified activin receptor ligand) produced through complex biologic manufacturing. Addresses a previously unmet need in reducing transfusion burden.
Help paying for Reblozyl
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
BMS Access Support Co-Pay Assistance Program helps eligible commercially insured patients with co-pays or co-insurance for Reblozyl. Government insurance is not eligible.
For: private insurance · source - Insurance and case manager help
Helps with benefits checks, prior authorizations and appeals, and refers patients to independent charitable foundations. Mon-Fri 8 AM-8 PM ET.
The official page does not say who qualifies. Ask the program. · source
Good to know: Reblozyl is marketed in the US by Bristol Myers Squibb (licensed from Merck). Medicare/Medicaid/TRICARE patients can't use the BMS co-pay program but may be referred to independent foundations. Ask BMS Access Support whether the BMS Patient Assistance Foundation covers Reblozyl.
- From a charity · Cooley's Anemia FoundationSupport for Significant Travel to Treatment Centers fundApply directly
Pays for: Travel to a major thalassemia treatment center for comprehensive care, up to $500 per year.
The foundation says: “Status not shown on page”
Clinical trial results
The BELIEVE trial showed 21.4% of luspatercept-treated patients achieved a 33% or greater reduction in transfusion burden versus 4.5% on placebo. The later BEYOND trial studied adults with non-transfusion-dependent beta-thalassemia; the US label does not cover that group.
Development history
Developed by Acceleron Pharma (acquired by Merck in 2021) and co-marketed by Bristol Myers Squibb. Approved November 2019 for beta-thalassemia. Later expanded to lower-risk MDS in 2020. Represents the first targeted therapy for thalassemia-related anemia.
Explore Beta-Thalassemia trials
Other Beta-Thalassemia treatments
Common questions about Luspatercept
▸What is Luspatercept (Reblozyl)?
The first drug approved specifically for anemia in beta-thalassemia patients who require regular blood transfusions. Reblozyl helps the body mature its own red blood cells more effectively, reducing the need for transfusions.
▸How does Luspatercept work?
In beta-thalassemia, the body produces defective hemoglobin, leading to ineffective red blood cell production. Immature red blood cells die before they mature.
Luspatercept acts as a trap for certain growth factors (TGF-beta superfamily ligands) that block the final stages of red blood cell development. By removing these blockers, it allows more red blood cells to fully mature and enter the bloodstream.
▸What are the side effects of Luspatercept?
Common side effects include headache, bone pain, joint pain, fatigue, cough, abdominal pain, diarrhea, and dizziness. Thromboembolic events (blood clots) have been reported. Blood pressure should be monitored. In beta-thalassemia, extramedullary hematopoietic masses can form and occasionally press on the spinal cord. May harm a developing baby; use effective birth control during treatment and for 3 months after.
▸How is Luspatercept taken?
Given as a subcutaneous injection once every 3 weeks. Starting dose is 1 mg/kg, which can be titrated up to 1.25 mg/kg based on response. It is mixed and given by a healthcare professional, and hemoglobin is checked before each dose.
▸Is Luspatercept FDA approved?
Yes, Luspatercept (Reblozyl) is FDA approved (2019) for the treatment of Beta-Thalassemia.
▸How does luspatercept reduce the need for blood transfusions?
In beta-thalassemia, immature red blood cells die before maturing. Luspatercept traps TGF-beta superfamily ligands that block late-stage red blood cell development. By removing these blockers, more red blood cells reach maturity and enter the bloodstream, raising hemoglobin and reducing transfusion dependence.
▸What did the BELIEVE trial demonstrate?
The BELIEVE trial showed 21.4% of luspatercept-treated patients achieved a 33% or greater reduction in transfusion burden versus only 4.5% on placebo. The later BEYOND trial studied non-transfusion-dependent beta-thalassemia, which the US label does not cover.
▸Is luspatercept also used for conditions other than thalassemia?
Yes. Luspatercept (Reblozyl) was initially approved for beta-thalassemia in November 2019, then expanded to lower-risk myelodysplastic syndromes (MDS) in 2020. The mechanism of promoting red blood cell maturation is relevant to both conditions.
▸How is luspatercept administered?
Luspatercept is given as a subcutaneous injection once every 3 weeks. The starting dose is 1 mg/kg, which can be increased to 1.25 mg/kg based on response. It is mixed and injected by a healthcare professional.
▸What monitoring is needed during luspatercept treatment?
Hemoglobin and transfusion needs are checked before each dose. Blood pressure is monitored because the drug can raise it, and doctors watch for blood clots and for extramedullary hematopoietic masses (clusters of blood-forming tissue outside the bone marrow that can press on the spine). The drug may harm a developing baby, and effective birth control is advised during treatment and for 3 months after.
▸How does luspatercept compare to gene therapy options for thalassemia?
Luspatercept is a chronic treatment reducing transfusion burden but not eliminating the underlying defect, while gene therapies like Casgevy and Zynteglo aim for a potential one-time functional cure. Luspatercept avoids the intensive conditioning chemotherapy required for gene therapy.
▸Who manufactures luspatercept?
Luspatercept was developed by Acceleron Pharma (acquired by Merck in 2021) and is marketed in the US by Bristol Myers Squibb, under license, as Reblozyl.